Although anti-tumor necrosis factor (TNF) therapy has revo-lutionised the management of spondyloarthritis (SpA), 20–30% of SpA patients discontinue biological treatment because they fail to respond or their response is inadequate, and 10–20% stop because of a lack or loss of efficacy or the onset of adverse events. Published data show that anti-TNF drugs in are highly effective in patients with ankylosing spondylitis, and associated with a higher drug persistence rate. Furthermore, studies suggest considering a switch to another anti-TNF drug if a first anti-TNF agent is discontinued because of loss of efficacy or adverse events.

Ankylosing Spondylitis Treatment after First Anti-TNF Drug Failure / M. Benucci, A. Damiani, F. Bandinelli, V. Grossi, M. Infantino, M. Manfredi, F.L. Gobbi, P. Sarzi-Puttini, F. Atzeni. - In: ISRAEL MEDICAL ASSOCIATION JOURNAL. - ISSN 1565-1088. - 20:2(2018 Feb), pp. 119-122.

Ankylosing Spondylitis Treatment after First Anti-TNF Drug Failure

P. Sarzi-Puttini;
2018

Abstract

Although anti-tumor necrosis factor (TNF) therapy has revo-lutionised the management of spondyloarthritis (SpA), 20–30% of SpA patients discontinue biological treatment because they fail to respond or their response is inadequate, and 10–20% stop because of a lack or loss of efficacy or the onset of adverse events. Published data show that anti-TNF drugs in are highly effective in patients with ankylosing spondylitis, and associated with a higher drug persistence rate. Furthermore, studies suggest considering a switch to another anti-TNF drug if a first anti-TNF agent is discontinued because of loss of efficacy or adverse events.
ankylosing spondylitis (AS); anti-tumor necrosis factor (anti-TNF) drugs; efficacy; adverse events
Settore MED/16 - Reumatologia
feb-2018
https://www.ima.org.il/FilesUpload/IMAJ/0/272/136247.pdf
Article (author)
File in questo prodotto:
File Dimensione Formato  
136247.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 130.76 kB
Formato Adobe PDF
130.76 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/640440
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact